Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Achieve Life Sciences Inc
ACHV | US
4.98
USD-0.10
-1.97%
ACHV | US
About Achieve Life Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
4.98
Open
5.01
High
5.08
Low
4.94
Achieve Life Sciences Inc. a clinical-stage pharmaceutical company develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada the United States and the United Kingdom. The company offers cytisinicline a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences Inc. is based in Vancouver Canada.
View LessACHV | US
Risk
41.9
Sharpe
0.36
Luna's Score
43/100
Recommendation
Sell
Luna says (ACHV | US)
What's Working
What's not Working
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
30.8%1 month
41.9%3 months
41.2%6 months
41.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.10
Debt to equity
0.42
Debt to assets
0.27
Ent. to EBITDA
-2.42
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-25.14M
MarketCap
171.02M
MarketCap(USD)
171.02M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-105.95
Short ratio
31.50
Short perc.
12.01
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.43
Range1M
0.99
Range3M
1.18
Volumes: Market Activity
Rel. volume
0.43
Price X volume
235.32K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.42 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.10 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 41.25 | - | Lower Risk |
| Debt to Equity | 0.42 | -1.23 | Expensive |
| Debt to Assets | 0.27 | 0.25 | Par |
| Market Cap | 171.02M | - | Emerging |
